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Abstract: In bone engineering, the adhesion, proliferation and differentiation of 
mesenchymal stromal cells rely on signaling from chemico-physical structure of the 
substrate, therefore prompting the design of mimetic “extracellular matrix”-like scaffolds. 
In this study, three-dimensional porous poly-L-lactic acid (PLLA)-based scaffolds have 
been mixed with different components, including single walled carbon nanotubes (CNT), 
micro-hydroxyapatite particles (HA), and BMP2, and treated with plasma (PT), to obtain 
four different nanocomposites: PLLA + CNT, PLLA + CNTHA, PLLA + CNT + HA + BMP2 
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and PLLA + CNT + HA + PT. Adult bone marrow mesenchymal stromal cells (MSCs) 
were derived from the femur of orthopaedic patients, seeded on the scaffolds and cultured 
under osteogenic induction up to differentiation and mineralization. The release of specific 
metabolites and temporal gene expression profiles of marrow-derived osteoprogenitors 
were analyzed at definite time points, relevant to in vitro culture as well as in vivo 
differentiation. As a result, the role of the different biomimetic components added to the 
PLLA matrix was deciphered, with BMP2-added scaffolds showing the highest biomimetic 
activity on cells differentiating to mature osteoblasts. The modification of a polymeric 
scaffold with reinforcing components which also work as biomimetic cues for cells can 
effectively direct osteoprogenitor cells differentiation, so as to shorten the time required  
for mineralization. 
Keywords: bone tissue engineering; biomimetic nanocomposites; mesenchymal stem cell 
 
1. Introduction 
The goal of tissue engineering is the regeneration of an adult damaged tissue, i.e., the restoration  
of the physical and mechanical nature of the native tissue [1,2]. Using an “extracellular matrix” 
(ECM)-like resorbable scaffold that cells can attach to, proliferate into, and migrate across, the 
damaged tissue may be replaced by the construct, which in turn is slowly resorbed and substituted by 
new functional tissue [3]. Therefore the process of tissue engineering starts with the sourcing of the 
relevant cells, to end with the full integration of the functional regenerated tissue into the host. 
Inflammation and scarcity of pluripotent stem cells or progenitors at the injury site could hamper 
the proper bone healing mechanisms; therefore the engraftment of mesenchymal stem cells has been 
shown to provide a potent cell therapy for tissue repair. Though the cells potentially useful include 
those derived from autologous, allogeneic or, possibly, xenogeneic sources, autologous cells are 
preferred in terms of availability and safety [4]. The degree of cell manipulation ex vivo will depend on 
the origin of the cells and the complexity of the tissue, but due to the artificial conditions of an  
in vitro culture, the phenotype of the cells has to be controlled during cell expansion [5]. 
To be engrafted in the living tissue adherent cells require a supporting structure, either a scaffold, a 
matrix, or a membrane, where new tissue will be generated in response to molecular and mechanical 
signals. The cell-material system is referred to as a construct, which is generated ex vivo, and has to be 
fully accepted by the host to achieve an effective regeneration of functional tissue [6]. 
Bone marrow-derived mesenchymal stromal cells (MSCs) are able to differentiate ex vivo along 
mesenchymal lineages, following in vitro expansion under the influence of specific chemicals [7].  
But differentiation of MSCs is also governed by other stimuli, such as chemistry, micro- and   
nano-topography, and rigidity of the substrate, as they usually do in vivo when embedded in the ECM. 
Therefore, an artificial scaffold for bone should be designed to be instructive to MSCs to undergo 
osteogenic maturation whereas accomplishing its mechanical tasks during the entire period of bone 
repair [8]. As a consequence, a biodegradable biomimetic material that induces or promotes significant Int. J. Mol. Sci. 2012, 13 2441 
 
 
new bone formation by osteogenic cells at an injured site is the desirable engineered substrate for 
orthopaedics [9,10]. 
Since natural bone is a reinforced organic/inorganic composite, i.e., collagen/hydroxyapatite (HA) 
composite, a polymer-based HA composite is a promising material for use as bone implant. Among 
biodegradable polymers used for bone engineering, poly-lactic acid (PLLA) has great modeling 
properties, controlled degradation with time and good tissue compatibility [11]. Nevertheless, the 
mechanical and surface properties of this material are unable to bear heavy loads and to stimulate cell 
adhesion, respectively. The addition of micro- and nanoparticles or fibers to the polymeric matrix may 
improve mechanical properties, and surface functionalization may promote bone cell adhesion [12]. 
In this study, a micro-macroporous PLLA matrix was synthesized, and then functionalized with 
different biomimetic signals, including (i) dispersion of single-wall carbon nanotubes (SWCNT, CNT 
for simplicity) and micro-hydroxyapatite particles (HA) in the matrix, to mimic bone constituents;  
(ii) plasma deposition to change the surface hydrophobicity; and (iii) loading of bone morphogenetic 
protein 2 (BMP2) as an osteogenic inducer. 
CNT and HA are supposed to closely approximate the function of HA crystals and collagen fibers 
in bone; moreover the release of Ca
2+ ions from HA should act as a buffer for acidic products of 
polymer degradation. HA particles have been shown to act as a reinforcing agent, but also as a source 
of calcium and phosphate easily recognized by osteoblasts as a “natural” mineral phase [13,14]. 
Plasma-based strategies for selective surface modification have been largely applied to hydrophobic 
polymeric scaffolds, such as PLLA, and enhanced interaction with cells has been observed [15,16]. 
Some of the scaffolds under assay have been loaded with BMP2, to serve as delivery vehicles for 
the growth factor. The bone-promoting activity of BMP2 in vitro and in vivo has been recognized and 
approved some years ago [17], even if the biologic potency of such growth factor in enhancing bone 
formation is still debated [18,19]. 
Theoretically, each of these signals may activate osteoprogenitor cells and genes, and consequently 
promote tissue growth and organization at the site of injury [20]. In this study the response of human 
MSCs to 3D PLLA-based scaffolds with controlled macro- and micro-structures prepared by Thermally 
Induced Phase Separation technique was assessed. The bioactive behavior was conferred to the 
polymer matrix by using four different strategies, including CNT and/or HA particles addition, BMP2 
loading, and plasma treatment of the surface. The osteoconductive properties of the different scaffolds 
have been verified by analyzing morphology, biochemistry and gene expression of human MSCs 
seeded on the scaffolds and cultured under osteogenic induction. 
2. Results and Discussion 
The reduction of time for fracture healing or the treatment of non-unions and joint diseases are 
current problems in orthopaedics, and regenerative strategies have been shown to have a high potential 
in favoring bone repair [21–23]. 
To avoid cell dispersion away from the injured site, MSCs are better delivered in vivo using a 
carrier, such as ceramic granules, fibrin, etc., which may also positively interact with the cells [24,25], 
or a scaffold, which provides a suitable ECM-like environment with signals for cell survival and 
functions, and may deliver additional growth factors. Several prefabricated polymer-cell constructs Int. J. Mol. Sci. 2012, 13 2442 
 
 
have been shown to assist host cells for attachment and subsequent proliferation and differentiation; 
since cells interact with ECM at both micro- and nano-scale level, the addition of micro- and   
nano-sized components to bulk materials during matrix manufacturing is likely to enhance cell 
response [26–28]. In this study the osteoconductive properties of some composites were evaluated by 
using a combination of morphological, biochemical and molecular assays [4]. Four types of scaffolds 
were prepared and assayed, including: PLLA + CNT, PLLA + CNT + HA, PLLA + CNT + HA + BMP2, 
and +PLLA + CNT + HA+ “plasma enhanced chemical vapor deposition (PECVD)-treatment” (PT). 
The PLLA-based scaffold prepared in this study had a mean pore diameter of 103 μm, and a mean 
porosity of 87%, as measured by mercury intrusion porosimetry. Though slight differences in pore 
distribution, the scaffold architecture was similar (Figure 1, lane a). The Young modulus was   
12.5 ± 2.0 MPa and the maximum stress 0.39 ± 0.02 MPa. The hydrophobicity of the scaffolds was a 
potential drawback for cell inoculation, therefore the scaffolds were pre-wet with serum-added culture 
medium for two hours. 
Figure 1. Scanning electron microscopy (SEM) of the porous poly-L-lactic acid (PLLA) 
scaffolds kept for 7 days in mineralization medium without (a, bar = 1 mm) or with 
mesenchymal stromal cells (MSCs) (b, bar = 100 μm; c, bar = 10 μm). Images of lane a 
show that the micro/macro-porosity of the composites is slightly different. In lanes b and c 
MSCs are seen to spread, proliferate and show intercellular connections on all the 
composites. On PLLA + carbon nanotube (CNT) the cells do not form a continuous layer. 
Instead, on PLLA + CNT + micro-hydroxyapatite particles (HA) calcium phosphate nodules 
are clearly seen, and on PLLA + CNT + HA + plasma (PT) cells are multilayered. 
PLLA+CNT PLLA+CNT+HA PLLA+CNT+HA+BMP2 PLLA+CNT+HA+PT
75x
600x
1200x
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2.1. Cell Culture Characterization 
The following time points were considered for cell culture characterization: (i) in differentiation 
medium: 7 days (TD1) and 14 days (TD2) after seeding on nanocomposites; (ii) in mineralization Int. J. Mol. Sci. 2012, 13 2443 
 
 
medium: before cell seeding onto nanocomposites (TM0) and after 7 days (TM1). Scanning electron 
microscopy (SEM) was used to observe morphology and spreading of cells on the scaffolds (Figure 1, 
b and c); MSCs on “Tissue Culture Plastic Surface” (TCPS) were arranged as monolayers on 2D 
plastic surface (images not shown), and exhibited an exponential growth rate from TD1 to TD2, 
because the cells were seeded at low density (14,727 ± 214 cells/scaffold). On the contrary, from TM0 
to TM1 a modest increase in cell proliferation was observed, as cells were seeded at higher density  
(95,333 ± 2,353 cells/scaffold). The cells retrieved from 3D materials at different time points were 
even lesser in comparison with the number of seeded cells, but the addition of HA to the composite 
apparently enhanced the number of cells on the scaffolds, which was maximally increased in samples 
treated with PECVD (Figure 2a).  
Figure 2. (a) Data on the scaffold colonization are expressed as mean of the ratios (“ln” 
transformed) between number of cells recovered from each scaffold at the different end 
points and number of seeded cells; (b) In agreement with the number of recovered cells, 
the fluorescence emitted by the Alamar Blue dye is higher in Tissue Culture Plastic Surface 
(TCPS) cultures. All the cultures show an increase in fluorescence from TD1 to TD2, while 
from TM0 to TM1 the lowest signal is found in PLLA + CNT samples; (c) At TD1, 
alkaline phosphatase activity is lower in scaffolds than in TCPS, but it increases from  
TM0 to TM1 so that the enzyme activity at final end point is similar in 2D and 3D   
cultures; (d) The release of type I collagen is higher in 2D cultures, but the addition of 
bone morphogenetic protein 2 (BMP2) favors the collagen production during the   
mineralization phase. 
-,005
0
,005
,01
,015
,02
,025
,03
C
I
C
P
 
n
g
/
p
r
o
t
 
n
g
TD1 TD2   TM0 TM1
-,0002
0
,0002
,0004
,0006
,0008
,001
A
L
P
 
n
m
o
l
e
s
/
m
i
n
u
t
e
/
D
N
A
 
p
g
TD1 TD2   TM0 TM1
0
2000
4000
6000
8000
10000
R
e
l
a
t
i
v
e
 
F
l
u
o
r
e
s
c
e
n
c
e
 
U
n
i
t
TD1 TD2   TM0 TM1
TCPS CNT+HA+PT CNT+HA+BMP2 CNT+HA CNT
a) Scaffold colonization (Picogreen assay) b) Cell proliferation and viability (Alamar Blue test)
d) Type I collagen production (CICP immunoassay) d) Alkaline Phosphatase (Biochemical activity)
-4
-3
-2
-1
0
1
2
3
l
n
(
n
o
.
 
r
e
c
o
v
e
r
e
d
 
c
e
l
l
s
/
n
o
.
 
s
e
e
d
e
d
 
c
e
l
l
s
)
TD1 TD2   TM1
CNT vs TCPS  p= 0.008 
CNT+μHA vs TCPS  p= 0.03
CNT+μHA+BMP vs TCPS p= 0.005
CNT vs CNT+μHA+BMP p= 0.03
CNT vs CNT+μHA p= 0.008
CNT vs CNT+μHA+BMP p= 0.01
CNT vs CNT+μHA+PT p= 0.0008
TD2
CNT vs CNT+μHA+BMP p= 0.03
CNT vs CNT+μHA+PT p= 0.05
TM1
CNT vs TCPS  p= 0.01 
CNT+μHA vs TCPS p= 0.01
TD1
TM1
Cell seeding: 15,000 cells Cell seeding: 100,000 cells
-,005
0
,005
,01
,015
,02
,025
,03
C
I
C
P
 
n
g
/
p
r
o
t
 
n
g
TD1 TD2   TM0 TM1
-,0002
0
,0002
,0004
,0006
,0008
,001
A
L
P
 
n
m
o
l
e
s
/
m
i
n
u
t
e
/
D
N
A
 
p
g
TD1 TD2   TM0 TM1
0
2000
4000
6000
8000
10000
R
e
l
a
t
i
v
e
 
F
l
u
o
r
e
s
c
e
n
c
e
 
U
n
i
t
TD1 TD2   TM0 TM1
TCPS CNT+HA+PT CNT+HA+BMP2 CNT+HA CNT
a) Scaffold colonization (Picogreen assay) b) Cell proliferation and viability (Alamar Blue test)
d) Type I collagen production (CICP immunoassay) d) Alkaline Phosphatase (Biochemical activity)
-4
-3
-2
-1
0
1
2
3
l
n
(
n
o
.
 
r
e
c
o
v
e
r
e
d
 
c
e
l
l
s
/
n
o
.
 
s
e
e
d
e
d
 
c
e
l
l
s
)
TD1 TD2   TM1
CNT vs TCPS  p= 0.008 
CNT+μHA vs TCPS  p= 0.03
CNT+μHA+BMP vs TCPS p= 0.005
CNT vs CNT+μHA+BMP p= 0.03
CNT vs CNT+μHA p= 0.008
CNT vs CNT+μHA+BMP p= 0.01
CNT vs CNT+μHA+PT p= 0.0008
TD2
CNT vs CNT+μHA+BMP p= 0.03
CNT vs CNT+μHA+PT p= 0.05
TM1
CNT vs TCPS  p= 0.01 
CNT+μHA vs TCPS p= 0.01
TD1
TM1
Cell seeding: 15,000 cells Cell seeding: 100,000 cells
 Int. J. Mol. Sci. 2012, 13 2444 
 
 
The differences in cell attachment/proliferation were further confirmed by the Alamar Blue test 
(Figure 2b). Even if the fluorescent signals emitted by cells were steadily higher when MSCs were 
grown on TCPS than onto the nanocomposites, the fluorescence emission increased from TD1 to TD2 
in all the cultures, which means that cells were proliferating over all the scaffolds. At TM1 significant 
differences were found between TCPS and all the scaffolds, except for PLLA + CNT + HA + PT. 
MSCs cultured on PLLA + CNT samples exhibited the lowest signal. 
Alkaline phosphatase (ALP) activity was characterized by a large variability among individuals 
(Figure 2c). At TD1, it was significantly lower in both PLLA + CNT and PLLA + CNT + HA than in 
TCPS cultures. The enzyme activity of MSCs cultured on TCPS tended to be constant from TD1 to 
TM1, whilst it increased in cells cultured into the scaffolds after the addition of the mineralization 
medium, with a peak for PLLA + CNT + HA + BMP2 nanocomposites. 
Type I collagen production was high when cells were cultured on TCPS (Figure 2d). Unpredictably, 
the CICP release in 2D cultures (TCPS) was more variable than in 3D ones; therefore no significant 
difference was detected when TCPS was considered for statistical comparison. The collagen release 
tended to increase from TD1 to TD2, and significant differences were recorded when HA was inside 
the scaffolds. At M1, the addition of HA alone was not enough to support the collagen production, 
while significant differences in comparison to PLLA + CNT were detected for samples treated with 
PEVCD or added with BMP2. 
Though their in vivo safety is still controversial [29], CNT have been largely exploited as 
reinforcing agents [30], drug delivery [31], and bone repair [32], due to their unique chemico/physical 
and mechanical properties. In our hands, the CNT-added PLLA had a low osteoconduction ability, 
since adhesion, proliferation, differentiation and mineralization of MSCs were hampered in comparison 
to TCPS and the other composites. Such results are in agreement with a recent paper, where purified 
and dispersed CNT can induce actin bundling and proliferation decrease in cells [33]. The addition of 
HA micro-particles to the CNT-PLLA composite was a positive signal for MSC adhesion and 
proliferation. Indeed, the biomimetic role of HA as matrix filler in bone repair has been largely 
demonstrated  in vitro and in vivo [34,35]. Though not shown in this study, a role played by the 
increased stiffness of HA-added PLLA vs. plain PLLA in inducing spreading and “mesenchymal” 
migration of MSCs, may be hypothesized [36]. 
There were several limitations to a comprehensive characterization of MSCs inside the 3D structure, 
because HA microparticles were interfering with the analysis of the mineral deposited. However, 
biochemical tests showed that the addition of BMP2 to PLLA + CNT + HA composite promoted 
alkaline phosphatase (ALP) activity and type I collagen production, and this may be considered a proof 
of the osteogenic differentiation of MSCs. Concerning the surface treatment, it is well known that 
changes in matrix hydrophobicity can dramatically alter cell-matrix interactions and in turn have a 
profound impact on various cellular behaviors such as adhesion, shape, motility, cytoskeletal 
organization, and differentiation [10]. The plasma-treatment of PLLA scaffolds with oxygen using 
“plasma enhanced chemical vapor deposition” (PECVD) had a strong impact on the adhesion of 
osteoprogenitors, thus speeding the formation of a construct suitable for initiating a regenerative 
process. Plasma treatment of hydrophobic polymers is one of the approaches used for providing micro- 
and nano-metric alterations of the surface architecture to improve protein and cell adhesion [37,38], 
and this mechanism is likely to be implied in our samples treated with plasma. Finally, the loading of Int. J. Mol. Sci. 2012, 13 2445 
 
 
BMP2 in the PLLA matrix positively influences the late events in osteoblast maturation, i.e., 
differentiation/mineralization of MSCs. The induction of osteogenic markers by BMP2 administration 
is recurrently demonstrated in murine progenitor cells, whereas this effect is not reproducibly induced 
in vitro or in vivo in bone marrow-derived human MSCs [39–41]. Accordingly to other studies, we 
found a positive effect on in vitro osteogenesis using BMP2 within a “complex” 3D scaffold [42]. 
2.2. Gene Expression Analysis 
Gene expression analysis was used in order to explore all the cell functions that cannot be easily 
analyzed using morphological, cytochemical, and biochemical assays. In a previous study we used the 
microarray technology to define the gene expression patterns underlying the consecutive steps of 
human adult MSCs differentiating into mature osteoblasts [43]. Whilst more than two-hundred genes 
with a biological function relevant to osteogenesis were selected, in the current study we focused on  
(i) some bone-related genes, to analyze the osteoinductive properties of nanostructured scaffolds;   
(ii) some TGFß signaling related genes, to highlight the BMP2 activity, a molecule of the TGFß 
superfamily of proteins; and (iii) one gene belonging to the Wnt signaling related genes, which is 
strongly and uniquely upregulated during the mineralization phase (Table 1). The quantitative results 
of gene expression analysis are shown, taking into account the biological function of the gene of 
interest, in Figure 3. 
Table 1. List of selected genes. 
Gene Symbol  Gene  Function 
Expression in TCPS 
cultures [43] 
ALPL 
Alkaline phosphatase 
liver/bone/kidney  
Membrane bound glycosylated enzyme involved in 
matrix mineralization. 
↑ TD2  
BGLAP 
Bone gamma-
carboxyglutamate 
protein (Osteocalcin) 
Noncollagenous matrix protein is associated the 
calcium phosphate mineral phase of bone. BGLAP is 
the only gene that is expressed in osteoblasts but not 
in other cells.  
↑ TD2 
CLEC3B Tetranectin 
Matrix protein (plasminogen-binding) involved in 
mineralization process. 
↑ TD2 
COL12A1 
Type 12 collagen, 
alpha 1 chain  
Type 12 collagen is found in association with type 1 
collagen, an association that is thought to modify the 
interactions between collagen 1 and the surrounding 
matrix. 
↑ TD1, ↑ TD2 
COL1A1 
Type 1 collagen, alpha 
1 chain 
Type 1 collagen is a fibril-forming collagen found in 
most connective tissues and is abundant in bone, 
cornea, dermis and tendon. It comprises two α1 
chains and one α2 chain. 
↑ TD1, ↑ TD2 
COMP 
Cartilage oligomeric 
matrix protein 
Noncollagenous ECM protein; it is expressed in the 
hypertrophic chondrocytes and in osteoblasts around 
developing bone. 
↑ TD1, ↑ TD2,  
↑ TM1 
FZD8 Frizzled  homolog  8 
Receptor for the Wingless type MMTV integration 
site family of signaling proteins.  
↑ TM1 Int. J. Mol. Sci. 2012, 13 2446 
 
 
Table 1. Cont. 
Gene Symbol  Gene  Function 
Expression in TCPS 
cultures [43] 
IBSP Bone  sialoprotein 
Noncollagenous glycoprotein expressed in 
mineralized tissues; it mediates cell-to-matrix 
attachment and binds to calcium and HA. 
↑ TD1, ↑ TD2,  
↑ TM1 
POSTN Periostin 
Secreted protein expressed during osteoblastic 
differentiation and maturation and abundantly found 
in mineralized bone nodules in vitro. 
↑ TD1, ↑ TD2 
Runx2 
Runt-related 
transcription factor 2  
Trascription factor belonging to the TGFß signaling 
pathway; it is considered a master regulatory switch 
to address the commitment of MSC to osteoblastic 
differentiation and skeletal morphogenesis. 
↑ TD1, ↑ TD2 
Smad4 
Mothers against 
decapentaplegic 
homolog 4 
Smad 4 is a common partner of BMP- and  
TGFß-receptor Smads; Smad4 induces expression of 
Runx2 and Osterix in osteoprogenitor cells. 
↑ TD1 
SP7 
Sp7 transcription 
factor (Osterix) 
SP7 is a transcription factor which acts downstream 
of Runx2 to induce osteoblastic differentiation in 
osteochondroprogenitor cells. Sp7 is responsible for 
the activation of BGLAP and COLA1 genes. 
↑ TD1 
SPARC Osteonectin 
Matrix-associated protein expressed in bone 
remodeling areas; it regulates angiogenesis and  
cell-matrix interactions. 
↑ TD1, ↑ TD2 
THBS1 Thrombospondin  1 
THBS1 is a negative regulator of TGFß signaling. It 
co-localizes with TGFß and mediates cell-to-cell and 
cell-to-matrix interactions. 
↑ TD1, ↑ TD2 
TNFRSF11B 
Tumor necrosis factor 
receptor superfamily, 
member 11b 
(osteoprotegerin) 
Osteoblast-secreted decoy receptor that functions as 
a negative regulator of bone resorption.  
↑ TD2 
Genes belonging to the TGFß signaling were tested only during the differentiation steps because 
they are expected to be up-regulated quite early along MSC culture (Figure 3a–d). Generally, the 
expression of these genes was decreased in cells cultured into the scaffolds. Smad4 increased in MSCs 
cultured onto TCPS and BMP2-added composites, while no changes were observed in cells colonizing 
other materials. Runx2 expression was similar in TCPS and PLLA + CNT + HA, while with the other 
scaffolds it decreased. Sp7 expression was widely influenced by the presence of BMP2, even if the 
responsiveness varied among individuals. The expression of THBS1, a negative regulator of TGFß 
signaling, was not influenced by the culture on composites, even if a lower amount of transcripts was 
observed in samples with BMP2. Collectively, genes belonging to TGFβ signaling were downregulated 
when cells were cultured into the scaffolds. The addition of BMP2 limited the decrease in Smad4 
expression and favored the expression of SP7, a transcription factor which acts downstream of Runx2 
to induce osteoblast differentiation in osteochondroprogenitor cells [44,45]. Although Smads are 
critical mediators in the TGFβ signaling pathway, BMP2 can activate Smad-independent pathways, 
including mitogen-activated protein kinases that have distinct roles in regulating alkaline phosphatase 
and osteocalcin expression in osteoblastic cells [46]. Moreover, a lower amount of THS1 transcripts is Int. J. Mol. Sci. 2012, 13 2447 
 
 
observed in samples exposed to BMP2: since it is an inhibitor of bone mineralization and matrix 
production, its low expression could be considered as a signal favoring osteogenesis [47]. 
Figure 3. Gene expression analysis. Graphs show the results of the Real Time PCR 
expressed as mean ± SEM of the ratios among “genes of interest” and GAPDH. The gene 
expression has been evaluated at T0 (before the seeding on nanocomposites) and TD2, or 
at TM0 and TM1. The asterisks mean the presence of statistical significant differences at 
that time point, and p values are referred in the text. 
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In the first 14 days of culture, the ALPL expression was similar in MSCs on TCPS and MSCs on 
nanocomposites (data not shown). During the mineralization phase the amount of ALPL transcripts 
diminished in cells cultured onto the scaffolds, and this decrease was less pronounced in materials with 
BMP2 (Figure 3e).  
During the mineralization period the expression of noncollagenous proteins was lower in MSCs 
cultured on nanocomposites, with significant differences in IBSP expression found between TCPS and 
PLLA + CNT (p = 0.05), and between TCPS and PLLA + CNT + HA (p = 0.05) (Figure 3k). The 
expression of COMP, SPARC and POSTN did not change significantly in comparison to   
TCPS (Figure 3j–m, respectively). Generally, the expression of noncollagenous proteins in PLLA + 
CNT + HA + BMP2 composite was close to that observed in cells cultured on TCPS, and even higher 
in the case of BGLAP (Figure 3f) and POSTN (Figure 3l). The only exception was CLEC3B, which 
was significantly less expressed in MSCs on the BMP2-added nanocomposite than in PLLA + HA  
(p = 0.003) (Figure 3g). The expression of COL1A1 and COL12A1 (Figure 3h,i, respectively) was 
decreased in MSCs on nanocomposites through the mineralization. The negative effect was weakened 
by the presence of BMP2. At TM1, the collagen expression in PLLA + CNT + HA + BMP2 
composites was significantly higher than in PLLA + CNT + HA + PT (COL1A1 p = 0.02; COL12A1  
p = 0.05). Summarizing, the most significant results were obtained by analyzing the expression of 
bone-related genes, especially during the mineralization phase. A decrease of ALP transcripts was 
evident in all the scaffolds, but it was less pronounced using PLLA added with BMP2. A correlation 
between gene expression and biochemical activity was not found, likely due to the high variability of 
the results.  
It is known that bone formation by osteoblastic cells requires the deposition of an extracellular 
matrix, consisting of collagen, a variety of fibrous and non-fibrous proteins, and glycosaminoglycans, 
to undergo mineralization upon formation of hydroxyapatite crystals. Type I collagen fibers are 
involved in aligning the mineral crystals, thus playing a pivotal role in mediating the apatite   
formation in normally mineralizing vertebrate tissues [48]. Noncollagenous proteins, including 
BGLAP/osteocalcin [49], CLEC3B/tetranectin [50], IBSP/bone sialoprotein [51], SPARC/osteonectin [52] 
and POSTN/periostin [53], comprise 10% of the organic matrix of bone. These proteins are expressed 
in areas of active remodeling, bind the hydroxyapatite crystals, and promote relevant functions in the 
regulation of mineralization. COMP/Cartilage oligomeric matrix protein is a prominent noncollagenous 
component of cartilage extracellular matrix, but it has also been localized in osteoblasts. COMP 
counteracts the activity of “extracellular matrix protein 1”, which inhibits the matrix mineralization  
and endochondral bone formation in the growth plates [54]. The expression of collagen and 
noncollagenous proteins was decreased in MSCs cultured into the scaffolds. The negative effect was 
counteracted by the presence of BMP2, which limited the downregulation observed with nanocomposites, 
and increased remarkably the expression of BGLAP/osteocalcin and POSTN/periostin, while 
CLEC3B/tetranectin was significantly decreased. Here, we have no sufficient information to explain 
why CLEC3B behaved differently in comparison to the other noncollagenous proteins. Other Authors 
found that dexamethasone and TGFß1 used simultaneously may inhibit the expression of tetranectin in 
SV-HFO osteoblastic cells [55]. 
The TNFRS11 expression did not differ between MSCs cultured on the scaffolds and MSCs on 
TCPS (Figure 3n), but a decrease was observed after the addition of the mineralizing medium in cells Int. J. Mol. Sci. 2012, 13 2449 
 
 
exposed to BMP2. The physiological role of osteoprotegerin, which increases during osteoblast 
differentiation, is the inhibition of osteoclastogenesis, but its expression must decrease in mineralizing 
osteoblasts when starts the “reverse phase” leading to bone resorption [56]. Therefore, this finding 
further confirms that the mineralization process is favored by BMP2 released from bioactive 
nanocomposites. 
Wnt signaling related genes. WNT signals are transduced through transmembrane-type WNT 
receptors encoded by Frizzled (FZD) genes. FZD8 is a frizzled receptor for the canonical   
Wnt-signaling pathway, which plays a critical role in skeletal development and osteogenesis, 
promoting the differentiation of mesenchymal cells into osteoblasts, and inhibiting their differentiation 
into chondrocytes and adipocytes [57]. FZD8 is constantly upregulated during the formation of mineral 
nodules, even though its function in driving the mineralization process has not been elucidated [8,43]. 
We confirmed the up-regulation of this receptor after addition of mineralizing agents (Figure 3o); 
however, no changes were observed whether MSCs were cultured onto TCPS or scaffolds, suggesting 
that the microenvironment is not relevant in influencing the expression of this receptor. 
Even though our data show that gene expression may be influenced by the various nanocomposites, 
significance following statistical analysis was found only when very large differences were observed. 
In this regard, a scoring system was conceived for grading the performance of nanocomposites in 
comparison to TCPS, assuming TCPS as the standard culture condition where the ability of MSC to 
generate new bone is proven by the deposition of mineral nodules. The score was calculated for each 
experiment and for each ‘gene of interest/GAPDH’ ratio, and a value was assigned to each comparison 
according to the following criteria: 
3 = scaffold - to - TCPS equal or higher than 1.1; 
2 = scaffold - to - TCPS from 0.9 to 1.1; 
1 = scaffold - to - TCPS from 0.1 to 0.9; 
0 = scaffold - to - TCPS from −0.1 to 0.1; 
−1 = scaffold - to - TCPS from −0.9 to −0.1; 
−2 = scaffold - to - TCPS from −1.1 to −0.9 
−3 = scaffold - to - TCPS equal or lower than −1.1. 
The mean of score values obtained in each experiment for each gene, the sum of the mean scores 
obtained in both differentiation and mineralization phases, and the total sum of the mean scores are 
shown in Table 2. Data are shown as increments corresponding to 0.33, representing the accuracy of 
the measurements, since the mean score of each gene was calculated on the basis of three experiments. 
The best total score was observed for PLLA + CNT + HA + BMP2, followed by PLLA + CNT + HA 
and PLLA + CNT + HA + PT with similar values, and finally by PLLA + CNT. No remarkable 
differences in gene expression were observed during the first 14 days of culture, although the 
“differentiation score” of PLLA + CNT + HA and PLLA + CNT + HA + BMP2 showed a positive 
trend in comparison to TCPS. The “mineralization score” was significantly higher in PLLA + CNT + 
HA + BMP2 than in PLLA + CNT and PLLA + CNT + HA (Wilcoxon test, p = 0.005 and p = 0.017, 
respectively), while the difference against PLLA + CNT + HA + PT was not significant (p = 0.17). Int. J. Mol. Sci. 2012, 13 2450 
 
 
Table 2. Mean of score values (n = 3) calculated for each gene. 
Process  Gene  PLLA+CNT  PLLA+CNT+HA PLLA+CNT+HA+BMP  PLLA+CNT+HA+PT
Differentiation          
 ALP  −2.00 0.00  −1.33  −1.33 
 BGLAP  0.67  0.33  1.33  1.00 
 CLEC3B  0.33  −0.33  −0.33  −0.33 
 COL12A1  −0.33  −0.33 0.33  −0.67 
 COL1A1  0.33  0.33  −0.33 0.33 
 COMP  1.33  0.33  0.00  −0.33 
 IBSP  −0.33  −0.33 0.00  −0.67 
 Osx  −2.00  −0.67  −0.33  −2.00 
 POSTN  0.33  0.33  0.33  0.00 
 RUNX2  −2.67 0.33  0.67  −0.67 
 Smad4  0.00  0.33  0.33  1.00 
 SPARC  0.00  −0.33  −0.33  −0.33 
 THS1  0.33  0.33  0.33  0.33 
 TNFRS11  0.33  0.33  −0.33 1.00 
Differentiation Score 
a  −3.67  0.67  0.33  −2.67 
Mineralization          
 ALP  −1.67  −0.67  −1.67  −1.00 
 BGLAP  −0.33  −0.33 0.67  −0.33 
 CLEC3B  −1.00  −1.33  −1.67  −0.67 
 COL12A1  −1.00  −1.00  −0.33  −1.00 
 COL1A1  −1.67  −1.33  −1.00  −1.33 
 COMP  −2.00  −1.67  −0.33  −2.00 
 FZD8  0.33  −0.67  −0.33  −0.33 
 IBSP  −2.00  −2.00  −0.33  −1.67 
 POSTN  −0.33  −0.67 1.00  −1.00 
 SPARC  −1.33  −1.00  −0.33  −1.00 
 TNFRS11  −0.33  −1.00  −1.00 1.00 
Mineralization Score 
b  −11.33  −11.67  −5.33  −9.33 
Total score
c     −15.00  −11.00  −5.00  −12.00 
a = sum of the mean scores in differentiation; b = sum of the mean scores in mineralization;   
c = total sum of the mean scores. 
In our study, PLLA-based scaffolds were found more osteoconductive for human MSCs when 
micro-hydroxyapatite and, even more, BMP2 were included in the 3D matrix. These findings are in 
contrast with data from a recent study on similar disc-shaped composites seeded with rat marrow 
stromal cells [58], where PLLA + CNT + HA was compared with PLLA in presence or not of BMP2. 
In this study nor micro-hydroxyapatite particles nor BMP2 were found to consistently improve 
proliferation and osteogenic differentiation of rat precursors. Aside from scaffold shape, which itself 
may affect the final results, the discrepancy of our data with such results may be ascribed to a number 
of factors. First, an osteogenic medium with β-glycerophosphate was adopted from the seeding time of 
cells on the discs, while in our protocol β-glycerophosphate was added after the phase of MSC 
proliferation, i.e., on cells at 80% confluency. In our opinion the osteogenic induction of MSCs from Int. J. Mol. Sci. 2012, 13 2451 
 
 
an early stage of culture may in some way hamper cell proliferation in favor of differentiation, 
changing the well-known in vitro progression of MSCs through proliferation, matrix deposition and 
mineralization [59]. Second, different cell types may respond differently to the same substrate, and rat 
MSCs have been shown to be more sensitive to metabolites produced in culture than human MSCs [60]. 
Concerning the response to BMP2, the induction of different BMP-receptors and the possibility of a 
different intracellular pathway for rat MSCs compared to human MSCs may account for the dissimilar 
results [61,62]. 
3. Experimental Section 
3.1. Scaffold Preparation 
PLLA, with an inherent viscosity of 0.90–1.2 dL/g, an average molecular weight (Mw) and 
polydispersity (Mw/Mn) of 104,000 and 1.80 respectively (measured by gel-permeation chromatography), 
was supplied by Absorbable Polymers (Pelham, AL) and used as received. The CNTs (90% purity) 
were supplied by Thomas Swan & Co. Ltd., with diameters of about 2 nanometers and lengths of 
several microns. Commercial HA powder, with a mean particle size of 5 microns (HA), was purchased 
from Plasma Biotal (Plasma Biotal, Tideswell, Derbyshire, UK). 1,4-dioxane was obtained from Sigma 
Aldrich and used as received without further purification. 
Porous scaffolds were fabricated using a thermally induced liquid-liquid phase separation   
technique [63]. PLLA was dissolved in a 87/13 (v/v) mixture of 1,4-dioxane and distilled deionized 
water to a final concentration of 8% (w/v). To prepare the nanocomposite scaffolds, 0.08% w/v CNT 
and 0.08% w/v HA were added to 8% w/v PLLA solution, and the mixtures sonicated and warmed at 
ca. 63 °C in order to disperse the CNT and HA completely. Then, the homogeneous dispersion was 
fast-frozen at −16 °C overnight to induce liquid-liquid phase separation. Finally, solvents were removed 
by freeze-drying for six days. 
The composites were prepared as three-dimensional scaffolds (3 × 3 × 3 mm) made of 8% w/v 
PLLA porous matrix with 1% wt CNT added or not with 1% wt HA. Some scaffolds were further 
added with 100 ng/scaffold BMP2, while other scaffolds were treated with PECVD technique as 
detailed elsewhere (PT) [64]. 
3.2. Cell Culture 
Bone marrow samples were collected by reaming the metaphysis and proximal diaphysis of the 
femur of three donors (#3002, male, 49 years; #3080, male, 46 years; #3369, female, 75 years), who 
had been scheduled for reconstructive joint surgery. The sample collection was approved by the 
Institutional Ethical Committee for human research. MSC were obtained as previously reported [4,43]. 
Briefly, marrow was filtered to remove bony fragments, diluted, and stratified on Ficoll-Hypaque 
gradient (Sigma, Milan, Italy) to collect mononuclear cells, which were seeded at a density of   
250,000 cell/cm
2 in α-MEM supplemented with 10% FBS, 100 U/mL penicillin, 0.1 mg/mL streptomycin, 
and 100 μmol/L ascorbic acid-2 phosphate (Sigma) (control medium). The cultures were incubated at 
37 °C in 95% air/5% CO2, and after 4 days the adherent cells (MSCs) were detached (T0) and about 
15,000 cells (14,727 ± 214) were seeded on the 3 mm
3 scaffolds with control medium added with  Int. J. Mol. Sci. 2012, 13 2452 
 
 
10
−8 M dexamethasone (differentiation medium). The constructs were maintained in a 96-well plate for 
14 days. Flow cytometry analysis confirmed that cells at the first confluence on tissue culture 
polystyrene (TCPS) expressed typical MSC surface antigens, including high levels of CD44, CD90, 
CD105, CD166 (>90%), while the percentages of CD45 and CD117 were very low (<1%) 
(Instrumentation Laboratory, Milan, Italy) [65].  
In order to analyze the mineralization ability of MSCs, about 100,000 cells (95,333 ± 2,353) from 
the second confluence were seeded on the PLLA scaffolds or on TCPS, and cultured for 7 days in 
medium containing 10 mM β-glycerophosphate (Sigma) (mineralization medium). At the final time 
point, the formation of mineral nodules in cultures on TCPS was assessed. Morphological, biochemical 
and molecular assays were performed before the seeding of MSCs on nanocomposites (T0), in 
differentiation medium (7 days-TD1 and 14 days-TD2 from the seeding), and in mineralization 
medium (before cell seeding onto nanocomposites-TM0 and after 7 days-TM1). 
3.3. Morphological Assays 
Density and morphology of MSCs on TCPS was monitored by light microscopy throughout the 
culture period, until the mineral deposition (data not shown). 
Morphology and spreading of cells on the scaffolds was observed by scanning electron microscopy 
(SEM). The samples were fixed with Karnovsky’s fixative (2% paraformaldehyde, 2.5% glutaraldehyde 
and 0.1 M sodium cacodylate buffer, pH 7.2–7.4) for 1 h, then post-fixed in 1% osmium tetroxide, 
dehydrated in ascending ethanol concentrations and dried in hexametildisilazane. All specimens were 
then coated with palladium-gold before being examined in a Philips SEM 515 at a voltage of 15 kV.  
3.4. Biochemical Assays 
Biochemical analyses were performed at TD1, TD2, and TM1. The number of cells within the 
scaffolds was determined using the Picogreen assay (Quant-IT Picogreen dsDNA, Life technologies, 
Monza, Italy). Cells were lysed with 0.01% sodium dodecyl sulphate and sonication, and 10 μL of cell 
lysate or standard were mixed with 10 μL of Picogreen solution in wells of a 96-well plate. The 
fluorescence was read at 480–520 nm with a microplate fluorescence reader CytoFluor 2350 (Millipore 
Corp., Bedford, MA, USA). The mean DNA content of the cells was defined by interpolation of values 
from a standard curve, then the number of cells was calculated from the Picogreen test results. 
The number of cells recovered from cultures at each endpoint was calculated by interpolating the 
DNA content with a standard curve, and extrapolating how many MSCs colonized the scaffold. Data 
were “ln” transformed to better highlight the average deviations from the baseline (= 0), represented by 
the number of seeded cells. 
Cell viability was assessed by the Alamar Blue test (Serotec Ltd, Oxford, UK), by following the 
manufacturer’s recommendations. Briefly, the Alamar Blue solution was added (10% v/v) to the 
culture. After incubation for 4 h at 37 °C the fluorescence was measured using the microplate 
fluorescence reader, with an excitation wavelength of 490 and an emission wavelength of 530 nm. The 
results were expressed as relative fluorescence units (RFUs). Int. J. Mol. Sci. 2012, 13 2453 
 
 
Alkaline phosphatase (ALP) was measured using a biochemical method (Sigma, N7653) in cell 
lysates obtained with 0.01% SDS, and the ALP activity expressed as nanomoles of p-nitrophenol 
formed per minute normalized to the cell number, as assessed from DNA content. 
The synthesis of type I collagen was assessed by measuring its metabolic product released in the 
culture supernatant. Levels of C-terminal propeptide of type I collagen (CICP) were quantified by enzyme 
immunoassay, according to the manufacturer’s instructions (Quidel Corporation, Heidelberg, Germany). 
3.5. Gene Expression Analysis 
The gene expression of MSCs was evaluated at TM0, i.e., before cell seeding onto nanocomposites 
for mineralization, and at TD1, TD2, and TM1 after cell seeding. At fixed time points, cells were 
collected and total RNA isolated on RNeasy micro and mini kits (Qiagen, GmbH, Hilden, Germany), 
following the manufacturer’s recommendations. RNA was treated with DNase (Qiagen), eluted in  
14 µL of RNase-free water and stored at −80 °C. RNA concentration and purity were determined by 
spectrophotometry (NanoDrop
® ND-1000, NanoDrop technologies). The retrotranscription was 
performed with MuLV Reverse Transcriptase (Applied Biosystems, Foster City, CA, USA), according 
to the manufacturer’s instructions. Real time PCR was performed by using the Light Cycler instrument 
and the Universal Probe Library system (Roche Applied Science, Monza, Italy) [66]. ProbeLibrary 
probes and primers were selected using a web-based assay design software (Probe Finder) [67]. 1 μg of 
cDNA was amplified, and the corresponding threshold cycle was referred to an eight-point standard 
curve. An housekeeping gene (GAPDH) was used as a references to normalize Real Time PCR data, 
which were expressed as ratio of “gene of interest” to GAPDH. 
3.6. Statistical Analysis 
Statistical analysis was performed using StatView 5.01 for Windows software (SAS Institute Inc., 
Cary, NC). Data were expressed as arithmetic mean plus and minus the standard error of the mean 
(SEM) of three separate experiments. A paired analysis of the data (Wilcoxon signed rank test) was 
applied to detect the effects of the treatments. Because of the low number of experiments, the results 
analysed with the “Wilcoxon Rank Sum test” may produce misleading results. In particular, we can 
fail in rejecting the null hypothesis when the null hypothesis is true, i.e., the addition of biomimetic 
signals to the nanocomposite has no consequences. In order to minimize the type I error rate, the 
significance level was fixed at 0.05. 
In order to quantify objectively the gene expression results, a scoring system was conceived for 
grading the performance of nanocomposites in comparison to TCPS. The calculation was performed 
using a “Microsoft
® Excel 2002” file, and a pivot table (Table 2) was obtained to summarize the mean 
of score values obtained in each experiment for each gene, the sum of the mean scores obtained in both 
differentiation and mineralization phases, and the total sum of the mean scores. 
 
4. Conclusions 
In this study the osteoconductive properties of four three-dimensional PLLA-based composites 
were evaluated by using a combination of morphological, biochemical and molecular assays. Int. J. Mol. Sci. 2012, 13 2454 
 
 
Collectively, our results show that human MSC adhesion, proliferation and osteogenic differentiation 
are modulated by the extracellular cues introduced in the polymeric 3D scaffolds. Particularly,   
CNT-added PLLA scaffold has a low osteoconductive ability, because neither adhesion nor 
proliferation or bone cell differentiation were promoted. Therefore, carbon nanotubes, though efficient 
in strengthening the polymeric matrix, do not provide MSCs with specific signals. In contrast, the 
addition of HA particles improves the performance of the PLLA + CNT composite, and plasma 
treatment further enhances MSC adhesion to the surface, as well as their proliferation and 
differentiation. The best results in terms of bone formation in vitro were obtained with the loading of 
BMP2 on the composite, as mineralization was promoted more than with any other scaffold. It may be 
suggested that the already osteoconductive PLLA/CNT/HA scaffold becomes “more osteoinductive”, 
too, when BMP2 is included. Indeed, the enrichment of the polymeric matrix with biomimetic signals 
enables a closer matching of scaffolds to the in vivo environment, and their sinergy strongly enhances 
the response of adult mesenchymal cells. 
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